Filing Details
- Accession Number:
- 0000886163-18-000140
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-10-02 18:24:13
- Reporting Period:
- 2018-10-01
- Accepted Time:
- 2018-10-02 18:24:13
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
886163 | Ligand Pharmaceuticals Inc | LGND | Pharmaceutical Preparations (2834) | 770160744 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1237556 | W Matthew Foehr | 3911 Sorrento Valley Boulevard, Ste 110 San Diego CA 92121 | President And Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-10-01 | 2,088 | $9.97 | 105,388 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2018-10-01 | 12,000 | $14.47 | 117,388 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-10-01 | 12,000 | $273.88 | 105,388 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2018-10-01 | 2,088 | $0.00 | 2,088 | $9.97 |
Common Stock | Employee Stock Option (right to buy) | Disposition | 2018-10-01 | 12,000 | $0.00 | 12,000 | $14.47 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
37,894 | 2021-04-18 | No | 4 | M | Direct | |
21,675 | 2022-02-09 | No | 4 | M | Direct |
Footnotes
- The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 24, 2018, in accordance with Rule 10b5-1.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.12 to $276.98, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11.
- Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12.